Regulatory regulators have approved PAPRi as a monotherapy for BRCA1/2 mutant breast and ovarian tumors, and concepts for DNA repair‐targeted therapy in malignancies with mutations in the BRCA1 or BRCA2 tumor suppressor genes are now available.150, 151, 152. This evidence concerns the gene BRCA1 and ovarian neoplasm.